The pandemic of COVID-19 in worldwide causes recent millions of morbidity and mortality in all countries and is the most important challenge in the world in recent years. Coronavirus is a single-stranded RNA virus and infection with COVID-19 leads to acute respiratory distress syndrome, lung inflammation, cytokine storm, and death. The other complications include endothelial dysfunction, activation of coagulation, thromboembolic events, and vascular disease. Cardiovascular complications such as myocardial and stroke ischemia, pulmonary thromboembolism, systemic arterial, and deep vein thrombosis were reported. In this review, we presented immuno-pathological mechanisms and the effects of COVID-19 on the cardiovascular system, heart, vessels, coagulation system, and molecular glance of immuno-inflammation to the COVID-19’s pathology on the cardiovascular system.
GustineJNJonesD.Immunopathology of hyperinflammation in COVID-19. Am J Pathol2021; 191(1): 4–17.
2.
AthariSS.COVID-19 pandemic is not apocalypse, is strong warning. Ann Immunol Immunother2020; 2(2): 000119.
3.
HuangCWangYLiXet al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet2020; 395: 497–506.
4.
WuCChenXCaiYet al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med2020; 180: 934–943.
5.
HamoucheWBisserierMBrojakowskaAet al. Pathophysiology and pharmacological management of pulmonary and cardiovascular features of COVID-19. J Mol Cell Cardiol2021; 153: 72–85.
6.
RuanQYangKWangWet al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med2020; 46: 846–848.
7.
Del ValleDMKim-schulzeSHsin-huiHet al. An inflammatory cytokine signature helps predict COVID-19 severity and survival. Nat Med2020; 26: 1636–1643.
8.
WadheraRKShenCGondiSet al. Cardiovascular deaths during the COVID-19 pandemic in the United States. J Am Coll Cardiol2021; 77(2): 159–169.
9.
FoxSEAkmatbekovAHarbertJLet al. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med2020; 8: 681–686.
10.
ChenGWuDGuoWet al. Clinical and immunological features of severe and moderate Coronavirus disease 2019. J Clin Invest2020; 130: 2620–2629.
11.
TayMZPohCMRéniaLet al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol2020; 20: 363–374.
12.
FinkSLCooksonBT.Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect Immun2005; 73: 1907–1916.
13.
HeLDingYZhangQet al. Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2 cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. J Pathol2006; 210: 288–297.
14.
Blanco-MeloDNilsson-PayantBELiuW-Cet al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell2020; 181: 1036.e9–1045.e9.
15.
KhosroshahiLMRokniMMokhtariTet al. Immunology, immunopathogenesis and immunotherapeutics of COVID-19: an overview. Int Immunopharmacol2021; 93: 107364.
16.
GubernatorovaEOGorshkovaEAPolinovaAIet al. IL-6: Relevance for immunopathology of SARS-CoV-2. Cytokine Growth Factor Rev2020; 53: 13–24.
17.
SatterfieldBABhattDLGershBJ.Cardiac involvement in the long-term implications of COVID-19. Nat Rev Cardiol2022; 19(5): 332–341.
18.
SurazakovAKlassenAGizingerO.The bioenergetics of COVID-19 immunopathology and the therapeutic potential of biophysical radiances. J Photochem Photobiol, B: Biol2020; 213: 112083.
19.
JiangSHillyerCDuL.Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol2020; 41(5): 355–359.
20.
JuBZhangQGeJet al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature2020; 584(7819): 115–119.
21.
St JohnALRathoreAPS. Early insights into immune responses during COVID-19. J Immunol2020; 205: 555–564.
22.
LiaoMLiuYYuanJet al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med2020; 26: 842–844.
23.
HadjadjJYatimNBarnabeiLet al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science2020; 369: 718–724
24.
ChenXYangXZhengYet al. SARS coronavirus papain-like protease inhibits the type I interferon signaling pathway through interaction with the STING-TRAF3-TBK1 complex. Protein Cell2014; 5: 369–381.
25.
ZhouYFuBZhengXet al. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. Natl Sci Rev2020; 7: 998–1002.
26.
MillsCDKincaidKAltJMet al. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol2000; 164: 6166–6173.
27.
YapJKYMoriyamaMIwasakiA.Inflammasomes and pyroptosis as therapeutic targets for COVID-19. J Immunol2020; 205: 307–312.
28.
LevettJYRaparelliVMardigyanVet al. Cardiovascular pathophysiology, epidemiology, and treatment considerations of coronavirus disease 2019 (COVID-19): a review. CJC Open2021; 3: 28–40.
29.
TikellisCThomasMC.Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease. Int J Pept2012; 2012: 256294.
30.
ZhengYYMaYTZhangJYet al. COVID-19 and the cardiovascular system. Nat Rev Cardiol2020; 17: 259–260.
31.
FangLKarakiulakisGRothM.Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?Lancet Respir Med2020; 8: e21.
32.
MyersLCParodiSMEscobarGJet al. Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California. JAMA2020; 323: 2195–2198.
33.
DiazJH.Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med2020; 27(3): taaa041.
34.
EslerMEslerD.Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?J Hypertens2020; 38: 781–782.
LippiGLavieCJSanchis-GomarF.Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): evidence from a metaanalysis. Prog Cardiovasc Dis2020; 63: 390–391.
37.
OnderGRezzaGBrusaferroS.Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA2020; 323: 1775–1776.
NapoliCTrittoIBenincasaGet al. Cardiovascular involvement during COVID-19 and clinical implications in elderly patients. A review. Ann Med Surg2020; 57: 236–243.
40.
SouthAMDizDIChappellMC.COVID-19, ACE2, and the cardiovascular consequences, Am J Physiol Heart Circ Physiol2020; 318: H1084–H1090.
41.
NasabMEAthariSS.Chest pain in COVID-19 patients may not refer to cardiac ischemia. J Med Microbiol Infect Dis2020; 8(3): 125–126.
42.
SandersJMMonogueMLJodlowskiTZet al. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA2020; 323: 1824–1836.
43.
LippiGSouthAMHenryBM.Electrolyte imbalances in patients with severe coronavirus disease 2019 (COVID-19). Ann Clin Biochem2020; 57: 262–265.
44.
BansalM.Cardiovascular disease and COVID-19. Diabetes Metab Syndr2020; 14: 247–250.
45.
HiranoTMurakamiM.COVID-19: a new virus, but a familiar receptor and cytokine release syndrome. Immunity2020; 52: 731–733.
46.
LiuBLiMZhouZet al. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?J Autoimmun2020; 111: 102452.
47.
RizzoPVieceli Dalla SegaFFortiniFet al. COVID-19 in the heart and the lungs: could we “Notch” the inflammatory storm?Basic Res Cardiol2020; 115: 31.
48.
Quiros RoldanEBiasiottoGMagroPet al. The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): a role for iron homeostasis?Pharmacol Res2020; 158: 104904.
49.
ZhouXLiLYangQ.Antiplatelet therapy after percutaneous coronary intervention in patients with COVID-19: implications from clinical features to pathologic findings. Circulation2020; 141: 1736–1738.
50.
VaduganathanMVardenyOMichelTet al. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med2020; 382: 1653–1659.
51.
KariyannaPTSutarjonoBGrewalEet al. A systematic review of COVID-19 and myocarditis. Am J Med Case Rep2020; 8(9): 299–305.
52.
ChenGWuDGuoWet al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest2020; 130(5): 2620–2629.
53.
WalshMNSorgenteAFischmanDLet al. The COVID-19 pandemic and cardiovascular complications: what have we learned so far?JACC Case Rep2020; 2(9): 1235–1239.
54.
OrtegaJTSerranoMLPujolFHet al. Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: an in silico analysis. EXCLI J2020; 19: 410–417.
55.
GiustinoGCroftLBOatesCPet al. Takotsubo Cardiomyopathy in COVID-19. J Am Coll Cardiol2020; 76(5): 628–629.
56.
YaoXHLiTYHeZCet al. A pathological report of three COVID-19 cases by minimal invasive autopsies. Zhonghua bing li xue za zhi = Chin J Pathol2020; 49(5): 411–417.
57.
VenugopalVKMahajanVRajanSet al. A systematic meta-analysis of CT features of COVID-19: lessons from radiology. medRxiv: the preprint server for health sciences. 2020; DOI: 2020.04.04.20052241.
58.
LiXMaX.Acute respiratory failure in COVID-19: is it “typical” ARDS?Crit Care2020; 24(1): 198.
59.
Leonard-LorantIDelabrancheXSeveracFet al. Acute pulmonary embolism in COVID-19 patients on CT angiography and relationship to D-dimer levels. Radiology2020; 296: E189–E191.
60.
FauvelCWeizmanOTrimailleAet al. Pulmonary embolism in COVID-19 patients: a French multicentre cohort study. Eur Heart J2020; 41(32): 3058–3068.
61.
NasabEMAthariSS.COVID-19 cytokine storm complications in asthmatic patients. Open Public Health J2020; 13: 625–626.
62.
TangNLiDWangXet al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost2020; 18(4): 844–847.
63.
VargaZFlammerAJSteigerPet al. Endothelial cell infection and endotheliitis in COVID-19. Lancet2020; 395(10234): 1417–1418.
64.
PoyiadjiNCormierPPatelPYet al. Acute pulmonary embolism and COVID-19. Radiology2020; 297(3): E335–E338.
65.
PoissyJGoutayJCaplanMet al. Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence. Circulation2020; 142(2): 184–186.
66.
PageEDAriënsRAS. Mechanisms of thrombosis and cardiovascular complications in COVID-19. Thromb Res2021; 200: 1–8.
67.
SrivastavaK.Association between COVID-19 and cardiovascular disease. IJC Heart Vasc2020; 29: 100583.
68.
RoifmanIAroraRCBewickDet al. Cardiovascular care delivery during the second wave of COVID-19 in Canada. Can J Cardiol2021; 37: 790e793.
69.
LeongDPBiostatMBanerjeeAet al. COVID-19 vaccination prioritization on the basis of cardiovascular risk factors and number needed to vaccinate to prevent death. Can J Cardiol2021; 37(7): 1112–1116.
70.
HantoushzadehSNabavianSMSoleimaniZet al. COVID-19 disease during pregnancy and peripartum period: a cardiovascular review. Curr Probl Cardiol2022; 47(1): 100888.
71.
BerryCMangionK.Cardiovascular complications are very uncommon in healthcare workers with mild or asymptomatic COVID-19 infection. JACC: Cardiovasc Imaging2021; 14(11): 2167–2169.
72.
CaoX.COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol2020; 20: 269–270.
73.
SchurinkBRoosERadonicTet al. Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. Lancet Microbe2020; 1: e290–e299.
74.
KunalSSharmaSMSharmaSKet al. Cardiovascular complications and its impact on outcomes in COVID-19. Indian Heart J2020; 72: 593e598.
75.
BoechatJLChoraIMoraisAet al. The immune response to SARS-CoV-2 and COVID-19 immunopathology-current perspectives. Pulmonology2021; 27(5): 423–437.
76.
RhaleteAEIRhaziIBensaidAet al. Cardiovascular injuries during COVID-19 infection: a PROCESS-compliant case series from the Eastern Morocco. Ann Med Surg2021; 65: 102309.
77.
MinhasAShadeJKChoSMet al. The role of sex and inflammation in cardiovascular outcomes and mortality in COVID-19. Int J Cardiol2021; 337: 127–131.
78.
GuijarroC.COVID-19 and cardiovascular disease. Clin Investig Arterioscler2020; 32(6): 263–266.
79.
DaiXOstrikovKK.ROS-Driven selection pressure on COVID-19 patients with cardiovascular comorbidities. Innovation. Epub ahead of print 27April2021. DOI: 10.1016/j.xinn.2021.100107.
80.
BonnieKYMannDL.COVID-19 clinical trials: a primer for the cardiovascular and cardio-oncology communities. JACC: Cardio Oncol2020; 2(2): 254–269.
81.
YiangouLDavisRPMummeryCL.Using cardiovascular cells from human pluripotent stem cells for COVID-19 research: why the heart fails. Stem Cell Rep J2021; 16: 385–397.
82.
MainesMZorziABenetolloPPet al. Short-term outcome associated with remote evaluation (telecardiology) of patients with cardiovascular diseases during the COVID-19 pandemic. IJC Heart Vasc2020; 30: 100625.
83.
EgeliBSparksJAKimAHJet al. Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: hero or villain?Best Pract Res Clin Rheumatol2021; 35: 101658.
84.
ZuoYKanthiYKnightJSet al. The interplay between neutrophils, complement, and microthrombi in COVID-19. Best Pract Res Clin Rheumatol2021; 35: 101661.
85.
García-GuimaraesMMojónDCalvoAet al. Influence of cardiovascular disease and cardiovascular risk factors in COVID-19 patients. Data from a large prospective Spanish cohort. RECCardio Clin2021; 56(2): 108–117.
86.
AldienASGanesanGSWahbehFet al. Systemic inflammation may induce cardiac injury in COVID-19 patients including children and adolescents without underlying cardiovascular diseases: a systematic review. Cardiovasc Revasc Med2022; 35: 169–178.
87.
BérardEKaiSHYColeyNet al. Lockdown-related factors associated with the worsening of cardiovascular risk and anxiety or depression during the COVID-19 pandemic. Prev Med Rep2021; 21: 101300.
88.
NaeiniMBSahebiMNikbakhtFet al. A meta-meta-analysis: evaluation of meta-analyses published in the effectiveness of cardiovascular comorbidities on the severity of COVID-19. Obes Med2021; 22: 100323.
89.
MedzikovicLCunninghamCMLiMet al. Sex differences underlying preexisting cardiovascular disease and cardiovascular injury in COVID-19. J Mol Cell Cardiol2020; 148: 25–33.
90.
WangSCWangYF.Cardiovascular protective properties of oxytocin against COVID-19. Life Sci2021; 270: 119130.
91.
LazaridisCVlachogiannisNIBakogiannisCet al. Involvement of cardiovascular system as the critical point in coronavirus disease 2019 (COVID-19) prognosis and recovery. Hell J Cardiol2020; 61: 381e395.
92.
LongJLuoYWeiYet al. The effect of cardiovascular disease and acute cardiac injury on fatal COVID-19: a meta-analysis. Am J Emerg Med2021; 48: 128–139.
93.
PolitoMVSilverioABellinoMet al. Cardiovascular involvement in COVID-19: what sequelae should we expect?Cardiol Ther Actions2021; 10(2): 377–396.
94.
NishigaMWangDWHanYet al. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol2020; 17: 543–558.
95.
TersalviGVicenziMCalabrettaDet al. Elevated troponin in patients with coronavirus disease 2019: possible mechanisms. J Card Fail2020; 26: 470–475.
96.
McGonagleDO’DonnellJSSharifKet al. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol2020; 2: e437–e445.
97.
TangNLiDWangXet al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost2020; 18: 844–847.
98.
TianSHuWNiuLet al. Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol2020; 15(5): 700–704.
99.
TangNBaiHChenXet al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost2020; 18(5): 1094–1099.
100.
FoxSEAkmatbekovAHarbertJLet al. Pulmonary and cardiac pathology in Covid-19: the first autopsy series from New Orleans. Lancet Respir Med2020; 8(7): 681–686.
101.
McGonagleDSharifKO’ReganAet al. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev2020; 19(6): 102537.
102.
JiHLZhaoRMatalonSet al. Elevated plasmin(ogen) as a common risk factor for COVID-19 susceptibility. Physiol Rev2020; 100: 1065–1075.
103.
ShoenfeldY.Corona (COVID-19) time musings: our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning. Autoimmun Rev2020; 19: 102538.
104.
NasabEMHeidarzadehSYavariBet al. Acute upper limb ischemia in a patient with COVID-19: a case report. Ann Vasc Surg2021; 77: 83–85.
105.
NasabEMHeidarzadehSAthariSS.Right atrial clot and pulmonary embolism in a patient with COVID-19: a case report. Radiol Case Rep2021; 16: 3392–3395.
106.
NasabEMAthariSS.Post-coronavirus era: should we expect a surge in allergic diseases and asthma?Open Public Health J2021; 14: 291–293.
107.
RivelleseFPredilettoE.ACE2 at the centre of COVID-19 from paucisymptomatic infections to severe pneumonia. Autoimmun Rev2020; 19(6): 102536.
108.
AthariSS.Targeting cell signaling in allergic asthma. Signal Transduct Target Ther2019; 4: 45.
109.
AthariSSAthariSM.The importance of eosinophil, platelet and dendritic cell in asthma. Asian Pac J Trop Dis2014; 4(Sup 1): S41–S47.
110.
Bagheri LankaraniKHonarvarBAthariSS. The mechanisms underlying helicobacter pylori-mediated protection against allergic asthma. Tanaffos2017; 16(4): 251–259.
111.
SasakiKMurataMNakamuraKet al. A case of severe COVID-19 with pulmonary thromboembolism related to heparin-induced thrombocytopenia during prophylactic anticoagulation therapy. Pulmonary artery problems in COVID-19. J Infect Chemother2022; 28(8): 1208–1211.
112.
PukONowackaASmulewiczKet al. Pulmonary artery targeted therapy in treatment of COVID-19 related ARDS. Literature review. Biomed Pharmacother2022; 146: 112592.
113.
HaddadzadehHRAthariSSAbediniRet al. One-Humped camel (Camelus dromedarius) infestation with linguatula serrata in Tabriz, Iran. Iran J Arthropod Borne Dis2010; 4(1): 54–59.
114.
RonconLZuinMBarcoSet al. Incidence of acute pulmonary embolism in COVID-19 patients: systematic review and meta-analysis. Eur J Intern Med2020; 82: 29–37.
115.
HamiMNaddafSRMobediIet al. Prevalence of Linguatula serrata infection in domestic bovids slaughtered in Tabriz Abattoir, Iran. Iranian J Parasitol2009; 4(3): 25–31.
116.
Cueto-RobledoGRoldan-ValadezEGraniel-PalafoxLEet al. Chronic thromboembolic pulmonary hypertension (CTEPH): a review of another sequel of severe post-covid-19 pneumonia. Curr Probl Cardiol. Epub ahead of print 25March2022. DOI: 10.1016/j.cpcardiol.2022.101187.
117.
ZotzmannVMueller-PeltzerKBodeCet al. Clinical implication of pulmonary artery thrombi in COVID-19. Respir Med2021; 176: 106247.
118.
PagnesiMBaldettiLBeneduceAet al. Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19. Heart2020; 106: 1324–1331.
119.
DhawanRTGopalanDHowardLet al. Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19. Lancet Respir Med2021; 9: 107–116.
